CCM
RPTX

CAAS Capital Management’s Repare Therapeutics RPTX Stock Holding History

CAAS Capital Management’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-50,000
Closed -$1.54M – 914
2020
Q3 		$1.54M Hold
50,000
– – 0.04% 289
2020
Q2 		$1.55M Buy
+50,000
New +$1.61M 0.05% 233

Other funds holding RPTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

CAAS Capital Management's RPTX Position: Q4 2020 in Review

CAAS Capital Management sold out of Repare Therapeutics (RPTX) in Q4 2020, closing a stake of 50,000 shares — an estimated $1.54M sold.

CAAS Capital Management first reported a position in RPTX in Q2 2020 and held it in 2 quarters. The position peaked at $1.55M in Q2 2020. 63 funds tracked by Wall St. Rank hold RPTX as of Q4 2020.

  • CAAS Capital Management reported no remaining Repare Therapeutics position as of Q4 2020 after selling out during the quarter.
  • CAAS Capital Management sold 50,000 Repare Therapeutics shares in Q4 2020, an estimated $1.54M.
  • CAAS Capital Management first reported a position in Repare Therapeutics in Q2 2020 and held it in 2 quarters.
  • CAAS Capital Management's Repare Therapeutics position peaked at $1.55M in Q2 2020.
  • 63 funds tracked by Wall St. Rank held Repare Therapeutics as of Q4 2020.

Based on CAAS Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.